The Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative™ is an unprecedented $100 million commitment over 10 years to support organizations working to address the HIV/AIDS epidemic in the Southern United States. The South is most affected by the HIV epidemic, accounting for 54% of all new HIV diagnoses in the U.S. In response to the Southern HIV epidemic, the initiative focuses on providing concentrated investments in the region to reduce HIV-related health disparities, build awareness, advance education, and reduce stigma. The Gilead COMPASS Initiative™ includes corporate giving programs, independent medical education grants, and the AIDSVu partnership.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead is a leading contributor to domestic and global HIV/AIDS funding, with $452 million in grants disbursed in 2016. They rank #1 in the total number of grants awarded, with 871 HIV/AIDS-related grants provided in 2016.
Through the corporate giving program of the Gilead COMPASS Initiative™, three Coordinating Centers - Emory University Rollins School of Public Health, University of Houston Graduate College of Social Work, and the Southern AIDS Coalition - will implement HIV-related programming and provide funding to local organizations that are committed to addressing the epidemic throughout the South. Community investment through grants, trainings, and shared learning opportunities will focus on three primary areas: (1) capacity building and shared knowledge; (2) wellbeing, mental health, substance use and trauma-informed care; and (3) awareness, education and anti-stigma campaigns. The COMPASS Initiative’s unique approach to addressing the HIV epidemic in the South is guided by five overarching principles.
Reflecting COMPASS’ commitment to data-driven programming, Gilead has also partnered with ETR to serve as the evaluator. Monitoring and evaluation systems are being established for the collection, analysis, and reporting of key evaluation data, with the purpose of informing continuous improvement. A non-profit organization that advances health equity by designing science-based solutions, ETR brings over three decades of experience in the field of HIV, sexual, and reproductive health. Most recently, with support from Gilead Sciences, ETR implemented the Intentional Advocates project which worked intensively with six organizations on capacity-building plans and aided their strategic communications and enhanced advocacy efforts in the South.
If you would like to learn more, then visit Gilead’s global and domestic investments.